Adree Khondker, Michael Groff, Sophia Nunes, Carolyn Sun, Natasha Jawa, Jasmine Lee, Vedran Cockovski, Yasmine Hejri-Rad, Rahul Chanchlani, Adam Fleming, Amit Garg, Nivethika Jeyakumar, Abhijat Kitchlu, Asaf Lebel, Eric McArthur, Luc Mertens, Paul Nathan, Rulan Parekh, Serina Patel, Jason Pole, Raveena Ramphal, Tal Schechter, Mariana Silva, Samuel Silver, Lillian Sung, Ron Wald, Paul Gibson, Rachel Pearl, Laura Wheaton, Peter Wong, Kirby Kim, Michael Zappitelli
BACKGROUND: Approximately 30% of childhood cancer survivors (CCSs) will develop chronic kidney disease (CKD) or hypertension 15 to 20 years after treatment ends. The incidence of CKD and hypertension in the 5-year window after cancer therapy is unknown. Moreover, extent of monitoring of CCS with CKD and associated complications in current practice is underexplored. To inform the development of new and existing care guidelines for CCS, the epidemiology and monitoring of CKD and hypertension in the early period following cancer therapy warrants further investigation...
2022: Canadian Journal of Kidney Health and Disease